Axio BioPharma

Executive Summary

Axio BioPharma is a San Diego-based private biotechnology company founded in 2018 that leverages AI-driven protein manufacturing to accelerate monoclonal antibody development. Operating as a specialized CDMO, it focuses on high-throughput, non-GMP process development and data-rich lab services, aiming to cut timelines and reduce costs for its clients. The company's core mission is to build an AI foundation for biologics manufacturing, enabling faster tech transfer and predictive control. By integrating AI into the development workflow, Axio offers a differentiated value proposition in the competitive CDMO market, addressing the industry's need for speed and efficiency in antibody production.

Upcoming Catalysts (preview)

• Q3 2026Strategic partnership with a top-20 pharma for AI-driven antibody development40% success
• Q2 2027Announcement of first GMP manufacturing capability expansion30% success
• Q4 2026Publication of validation data for AI-predicted manufacturability in peer-reviewed journal50% success